Evaluation of a five-gene signature associated with stromal infiltration for diffuse large B-cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34222425/
The top DEGs were identified, and the five hub genes were overexpressed in DLBCL. Furthermore, the gene alterations were confirmed and the positive correlation with tumor purity revealed the overexpression...
Toxicity and efficacy of chimeric antigen receptor T-cell in patients with diffuse large B cell lymphoma above the age of 70 years compare to younger patients - a matched control multi-center cohort study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34233446/
Data regarding efficacy and toxicity of Chimeric antigen receptor T cells (CAR-T) therapy in older aged -geriatric population are insufficient. Since 2019, Tisagenlecleucel and axicabtagene-ciloleucel were commercially approved for relapsed/refractory...
Pharmacologic targeting of Mcl-1 induces mitochondrial dysfunction and apoptosis in B-cell lymphoma cells in a TP53- and BAX- dependent manner - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34233959/
doi: 10.1158/1078-0432.CCR-21-0464. Online ahead of print. 1 Hematology & Hematopoietic Cell Transplantation, City Of Hope National Medical Center. 2 Computational biology, Oregon Health & Science University. 3 Department of Surgical...
The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34232979/
Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid malignancy affecting adults. NF-kB transcription factor family is activated by two main pathways, the canonical and the alternative NF-kB activation...
Allogeneic stem cell transplant in non-Hodgkin lymphomas: Still an indication? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34105814/
Allogeneic hematopoietic cell transplantation (alloHCT) used to play a defined role in the treatment of non-Hodgkin lymphoma (NHL). With the advent of modern targeted molecular therapies and immunotherapies, treatment standards...
-
Mark Fesler4yrI would agree with the authors that given the lower risks of CAR T cell therapy that alloSCT has been pushed back in the treatment algorithm to post CAR T Show More
-
Naveed Saleh, MD, MS – Skipta Team4yrKey Points • The authors of the current article pondered the conventional role of alloHCT in light of the emergence of modern targeted molecular therapies and immunotherapies for B-cell lymphoma. • “Although Show More